Clinical trial • Phase I • Oncology
MOMA-313 for Advanced or metastatic solid tumours
Phase I trial of MOMA-313 for Advanced or metastatic solid tumours. 125 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced or metastatic solid tumours
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-10-2024
- First CTIS Authorization Date
- 18-02-2025
Trial design
Phase I trial across 3 sites in Spain.
- Target Sample Size
- 125
Eligibility
Recruits 125 Vulnerable population selected (isVulnerablePopulationSelected=true). No details provided on consent or assent procedures or age-specific consent documents..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected=true). No details provided on consent or assent procedures or age-specific consent documents.
Recruitment
- Planned Sample Size
- 125
- Recruitment Window Months
- 20
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 125
Spain
- Earliest CTIS Part Ii Submission Date
- 23-01-2025
- Latest Decision Or Authorization Date
- 23-01-2026
- Processing Time Days
- 365
- Number Of Sites
- 3
- Number Of Participants
- 48
Sites
- Site Name
- Institut Catala D'oncologia
- Department Name
- Servicio de oncologia
- Principal Investigator Name
- Marta Gil Martin
- Principal Investigator Email
- mgilmartin@iconcologia.net
- Contact Person Name
- Marta Gil Martin
- Contact Person Email
- mgilmartin@iconcologia.net
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Servicio de oncologia
- Principal Investigator Name
- Joaquin Mateo Valderrama
- Principal Investigator Email
- jmateo@vhio.net
- Contact Person Name
- Joaquin Mateo Valderrama
- Contact Person Email
- jmateo@vhio.net
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Servicio de oncologia
- Principal Investigator Name
- Victor Moreno Garcia
- Principal Investigator Email
- victor.moreno@startmadrid.com
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- Moma Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MOMA-313
- Routes Of Administration
- Oral
- Route
- Oral
Related trials
Other published trials that may interest you.
- Inhibitor of the enzyme glucosaminyltransferase V for Advanced or metastatic solid tumours
- ART0380 MESILATE (alnodesertib) for Advanced or metastatic solid tumours
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer